# EDGAR Filing Document

**Accession Number:** 0001587788
**File Stem:** 0001628280-25-028824
**Filing Date:** 2025-6
**Character Count:** 9749
**Document Hash:** f9497a1ce5b482e3b7fe39d7f3e7ca9b
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001628280-25-028824.hdr.sgml**: 20250602

**ACCESSION NUMBER**: 0001628280-25-028824

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20250529

**FILED AS OF DATE**: 20250602

**DATE AS OF CHANGE**: 20250602

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Shepard Jay
- **CENTRAL INDEX KEY:** 0001587788

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-35986
- **FILM NUMBER:** 251014999

**MAIL ADDRESS:**
- **STREET 1:** 15977 GRANDVIEW AVENUE
- **CITY:** MONTE SERENO
- **STATE:** CA
- **ZIP:** 95030
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Esperion Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001434868
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 3891 RANCHERO DRIVE, SUITE 150
- **CITY:** ANN ARBOR
- **STATE:** MI
- **ZIP:** 48108
- **BUSINESS PHONE:** 734-887-3903

**MAIL ADDRESS:**
- **STREET 1:** 3891 RANCHERO DRIVE, SUITE 150
- **CITY:** ANN ARBOR
- **STATE:** MI
- **ZIP:** 48108

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** HDL THERAPEUTICS INC
- **DATE OF NAME CHANGE:** 20080513

## Ex-24

LIMITED POWER OF ATTORNEY

The undersigned hereby constitutes and appoints each of Sheldon Koenig and Benjamin Looker, signing singly, and with full

power of substitution, the undersigned's true and lawful

attorney-in-fact to:

(1) execute for and on behalf of the undersigned, in the

undersigned's capacity as an officer and/or director of Esperion

Therapeutics, Inc. (the "Company"), from time to time the

following U.S. Securities and Exchange Commission ("SEC") forms:

(i) Form ID, including any attached documents, to effect the

assignment of codes to the undersigned to be used in the

transmission of information to the SEC using the EDGAR System;

(ii) Form 3, Initial Statement of Beneficial Ownership of

Securities, including any attached documents; (iii) Form 4,

Statement of Changes in Beneficial Ownership of Securities,

including any attached documents; (iv) Form 5, Annual Statement

of Beneficial Ownership of Securities in accordance with Section

16(a) of the Securities Exchange Act of 1934, as amended, and the

rules thereunder, including any attached documents; (v) Schedule

13D and (vi) amendments of each thereof, in accordance with the

Securities Exchange Act of 1934, as amended, and the rules

thereunder, including any attached documents;

(2) do and perform any and all acts for and on behalf of the

undersigned which may be necessary or desirable to complete and

execute any such Form 3, 4 or 5, Schedule 13D or any amendment(s)

thereto, and timely file such form(s) with the SEC and any

securities exchange, national association or similar authority;

and

(3) take any other action of any type whatsoever in

connection with the foregoing which, in the opinion of such

attorney-in-fact, may be of benefit to, in the best interest of,

or legally required by, the undersigned, it being understood that

the documents executed by such attorney-in-fact on behalf of the

undersigned pursuant to this Power of Attorney shall be in such

form and shall contain such terms and conditions as such

attorney-in-fact may approve in such attorney-in-fact's

discretion.

The undersigned hereby grants to each such attorney-in-fact,

acting singly, full power and authority to do and perform any and

every act and thing whatsoever requisite, necessary or proper to

be done in the exercise of any of the rights and powers herein

granted, as fully to all intents and purposes as the undersigned

might or could do if personally present, with full power of

substitution or revocation, hereby ratifying and confirming all

that such attorney-in-fact, or such attorney-in-fact's substitute

or substitutes, shall lawfully do or cause to be done by virtue

of this power of attorney and the rights and powers herein

granted. The undersigned acknowledges that the foregoing

attorneys-in-fact, in serving in such capacity at the request of

------

the undersigned, are not assuming, nor is the Company assuming,

any of the undersigned's responsibilities to comply with Section

16 or Regulation 13D-G of the Securities Exchange Act of 1934, as

amended. The undersigned hereby agrees to indemnify the attorney

in fact and the Company from and against any demand, damage,

loss, cost or expense arising from any false or misleading

information provided by the undersigned to the attorney-in fact.

This Power of Attorney shall remain in full force and effect

until the undersigned is no longer required to file such forms

with respect to the undersigned's holdings of and transactions in

securities issued by the Company, unless earlier revoked by the

undersigned in a signed writing delivered to the foregoing

attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of

Attorney to be executed as of May 25, 2022.

/s/ Jay Shepard

________________

Jay Shepard

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Shepard Jay<br><sub>(Last) (First) (Middle)</sub><br>C/O ESPERION THERAPEUTICS, INC.<br>3891 RANCHERO DRIVE, SUITE 150<br><sub>(Street)</sub><br>ANN ARBOR, MI 48108<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2025-05-29 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director [ ] 10% Owner<br>[ ] Officer (give title below) [ ] Other (specify below)<br>_ _ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Esperion Therapeutics, Inc. [ ESPR ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common Stock | 2025-05-29 |  | A |  | 33000<sup>(1)</sup> | A | $0 | 84599 | D |  |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Stock Option (right to buy) | $0.87 | 2025-05-29 |  | A |  | 44000 |  | <sup>(1)</sup> | 2035-05-29 | Common Stock | 44000 | $0 | 44000 | D |  |

---

### Footnotes:

(1) The awards vest in full on the earlier of (i) May 29, 2026 and (ii) the Issuer's next annual meeting of stockholders following May 29, 2025.

**Signature:** /s/ Sheldon L. Koenig, by power of attorney  
**Date:** 2025-06-02

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**